share_log

康哲藥業:截至二零二四年四月三十日止月份之股份發行人的證券變動月報表

CMS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

Hong Kong Stock Exchange ·  May 6 05:49
Summary by Moomoo AI
康哲藥業控股有限公司(CMS)於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年4月30日的公司股份變動情況。報告顯示,公司的法定/註冊股本及已發行股份在4月份均無變動,維持在20,000,000,000股,每股面值0.005美元,總額100,000,000美元。此外,報告中確認了公司在4月份發行的證券已獲得董事會的正式授權,並且已履行了所有上市前的法定要求。公司秘書吳三燕負責提交本報告。
康哲藥業控股有限公司(CMS)於2024年5月6日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年4月30日的公司股份變動情況。報告顯示,公司的法定/註冊股本及已發行股份在4月份均無變動,維持在20,000,000,000股,每股面值0.005美元,總額100,000,000美元。此外,報告中確認了公司在4月份發行的證券已獲得董事會的正式授權,並且已履行了所有上市前的法定要求。公司秘書吳三燕負責提交本報告。
CONGE PHARMACEUTICAL HOLDINGS LIMITED (CMS) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 MAY 2024, REPORTING THE CHANGES IN COMPANY SHARES AS OF 30 APRIL 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged in April at 20,000,000,000 shares with a face value of $0.005 per share for a total of $100,000,000. In addition, the report confirms that the securities issued by the company in April have been formally authorized by the Board of Directors and have met all pre-listing regulatory requirements. Company Secretary Wu Sanyan is responsible for submitting this report.
CONGE PHARMACEUTICAL HOLDINGS LIMITED (CMS) FILED ITS LATEST SECURITIES CHANGE MONTH REPORT WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 6 MAY 2024, REPORTING THE CHANGES IN COMPANY SHARES AS OF 30 APRIL 2024. The report shows that the company's regulated/registered share capital and issued shares remained unchanged in April at 20,000,000,000 shares with a face value of $0.005 per share for a total of $100,000,000. In addition, the report confirms that the securities issued by the company in April have been formally authorized by the Board of Directors and have met all pre-listing regulatory requirements. Company Secretary Wu Sanyan is responsible for submitting this report.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more